MedTrace Logo

Radiolabelled IV and Oral Metabolism Study of F901318

NCT02912026 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-07-26

No results posted yet for this study

Summary

Open label radiolabelled metabolism study of intravenous and oral solution forms of F901318. Five healthy male subjects will receive IV and five will receive an oral solution. Blood, urine and faeces will be collected over a period adequate to obtain 90% recovery of parent compound and to determine the metabolic profile of both IV and oral forms.

Conditions

  • Invasive Aspergillosis

Interventions

DRUG

IV F901318

Metabolic profile AUC 0 to infinity

DRUG

Oral F901318

Metabolic profile AUC 0 to infinity

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • F2G Biotech GmbH

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02912026 on ClinicalTrials.gov